General Counsel, Medpace, Inc.
Founder and CEO
Dr. Jon Isaacsohn has more than 30 years of experience developing hundreds of drugs from protocol design to global submissions (including 30 NDAs) and was the co-founder of Medpace, Inc. He has decades of experience in academia, pharmaceuticals and clinical medicine. Dr. Isaacsohn formerly served as the Chief Medical Officer of Teva, where he was responsible for specialty drug development, including about 160 clinical trials, as well as the company’s New Therapeutic Entity Initiative, the safety of all marketed products and the Global Health Program.
Chief Medical Officer
Brian Murphy, MD, MPH is board-certified in infectious disease, internal medicine and pediatrics, and has more than 15 years of experience in clinical trial and drug development as an academic investigator and Vice President of Medical Affairs at Medpace. He has worked with large and small biopharmaceutical companies, government agencies, public-private partnership, and academic centers to achieve the approval of multiple products across various therapeutic areas.
Chief Translational Science Officer
Mary Bond, MS, MBA has more than 20 years of industry experience in early clinical development, leading numerous clinical pharmacology programs for both small and large molecules at SmithKline Beecham, GlaxoSmithKline, Cephalon, and Teva. She has been responsible for the design and oversight of more than 100 early phase studies and has contributed to more than 12 INDs/CTAs and 15 marketing applications both in the U.S. and abroad.